Skip to content
Home/GPs/Ibionext
Ibionext

Ibionext

Paris, France·Founded 2015··ibionext.com

iBionext is France's first Venture Studio dedicated to healthcare, specializing in the creation, development, and financing of innovative startups in biotech, medtech, digital health, and deep tech sectors. Founded in 2012 and based in Paris, it has co-founded and built multiple high-potential companies and raised over €600 million collectively since inception.

AUM
€600M
Funds
1
vintages 2018
Portfolio
4
Exits
2
SectorsHealthcareSoftwareTMTIndustrials

Key facts

HQParis, France
Founded2015

Recent exits

Chronolife
Healthcare · 2025 · 8yr hold
GrAI Matter Labs
TMT · 2023 · 7yr hold

Coverage notes

1 fund tracked, 6 portfolio companies (4 active · 2 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund Ibionext has raised, with its portfolio companies. Hand-checked from public filings.

1 fund
iBionext Growth FundVC
2018 · 8yr€90M4 active · 2 realized

Unrealized

4 held
BrainEverActive
HealthcareFrance· Entry 2017
PropheseeActive
TMTFrance· Entry 2014
T-HeartActive
HealthcareFrance· Entry 2018
HealthcareFrance· Entry 2016

Realized

2 exits
ChronolifeExited 2025
HealthcareFrance· Entry 2017
Liquidationto
GrAI Matter LabsExited 2023
TMTFrance· Entry 2016
Trade Saleto
Track Ibionext

Saved GPs appear in your watchlist, one click from your workspace.

About Ibionext

iBionext is France's first Venture Studio dedicated to healthcare, with €600 million of assets under management as of December 2024, founded in 2015 and headquartered in Paris. The firm specialises in the creation, development and financing of innovative startups in biotech, MedTech, digital health and deep tech sectors, combining venture capital deployment with active company-building expertise.

Investment thesis

iBionext combines venture studio operations (creating new companies internally) with traditional venture capital investments in external biotech, MedTech, digital health and deep tech startups. Investment stages span early-stage seed and Series A with selective growth-stage follow-on commitments. The venture studio model distinguishes iBionext from pure VC peers, enabling proactive company-building alongside selective external investments where market opportunities align with the platform's healthcare focus.

Recent activity

The platform tracks a single dedicated fund vehicle and 6 active portfolio companies across the venture studio and traditional VC programmes. As a venture studio with selective external investments, iBionext maintains long-duration positions aligned with the multi-year company-building cycles typical of healthcare innovation. Detailed buyer names and multiple data available on Pro at €29/month.

Last updated June 2026 · Sourced from public filings